COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order
COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and ...
The Manila Times10h
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
ZOLAR is a first-in-human, proof-of-concept and biodistribution trial that uses positron emission tomography (PET) to ...
High Content Screening Market worth US$2.19 billion in 2030 with 7.5% CAGR | MarketsandMarkets™
The global High Content Screening Market , valued at US$1.47 billion in 2024, is forecasted to grow at a robust CAGR of 7.5%, ...
EQS-News: SYNBIOTIC presents medical cannabis as a pastille for the German market for the first time
EQS-News: SynBiotic SE / Key word (s): Product Launch SYNBIOTIC presents medical cannabis as a pastille for the German market for the first time 01.04.2025 / 15:13 CET/CEST The issuer is solely ...
The Manila Times17h
ARTMS Drug Master File for Gallium Production Technology Referenced with Telix's Gozellix®
(ARTMS), a global leader in radioisotope production technologies, is pleased to announce that the drug master file (DMF) 1 ...